Literature DB >> 11723204

A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members.

S H Mead1, C Proukakis, N Wood, A H Crosby, G T Plant, T T Warner.   

Abstract

Hereditary spastic paraparesis (HSP) is a clinically and genetically heterogeneous neurodegenerative disorder characterised by progressive lower limb spasticity and weakness. Some forms have been associated with white matter lesions and complex phenotypes. This study was prompted by the diagnosis of multiple sclerosis (MS) in two sisters from a large pedigree with hereditary spastic paraparesis. Twelve affected members of the extended family were examined (MRI and EEG were carried out and evoked potentials measured in five), and historical information was obtained from six affected deceased persons. The inherited disease phenotype was confirmed as autosomal dominant hereditary spastic paraparesis associated with epilepsy in four affected persons. None of the extended family had evidence of MS. Genetic analysis of the family has shown linkage to chromosome 2p and sequencing of the spastin gene has identified a 1406delT frameshift mutation in exon 10. This kindred demonstrates the clinical heterogeneity of HSP associated with spastin mutations. The possible relevance of the concurrence of HSP and MS in the sib pair is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723204      PMCID: PMC1737657          DOI: 10.1136/jnnp.71.6.788

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  8 in total

1.  Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases.

Authors:  C Depienne; C Tallaksen; J Y Lephay; B Bricka; S Poea-Guyon; B Fontaine; P Labauge; A Brice; A Durr
Journal:  J Med Genet       Date:  2005-07-31       Impact factor: 6.318

2.  Exon deletions of SPG4 are a frequent cause of hereditary spastic paraplegia.

Authors:  Christel Depienne; Estelle Fedirko; Sylvie Forlani; Cécile Cazeneuve; Pascale Ribaï; Imed Feki; Chantal Tallaksen; Karine Nguyen; Bruno Stankoff; Merle Ruberg; Giovanni Stevanin; Alexandra Durr; Alexis Brice
Journal:  J Med Genet       Date:  2006-11-10       Impact factor: 6.318

3.  Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia.

Authors:  Moneef Shoukier; Juergen Neesen; Simone M Sauter; Loukas Argyriou; Nadine Doerwald; D V Krishna Pantakani; Ashraf U Mannan
Journal:  Eur J Hum Genet       Date:  2008-08-13       Impact factor: 4.246

4.  Troyer syndrome revisited. A clinical and radiological study of a complicated hereditary spastic paraplegia.

Authors:  Christos Proukakis; Harold Cross; Heema Patel; Michael A Patton; Alan Valentine; Andrew H Crosby
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

5.  The coexistence of multiple sclerosis and hereditary spastic paraparesis in a patient.

Authors:  Işıl Yazıcı; Nılufer Yıldırım; Yaşar Zorlu
Journal:  Neurol Int       Date:  2013-06-25

6.  A network biology approach to unraveling inherited axonopathies.

Authors:  Dana M Bis-Brewer; Matt C Danzi; Stefan Wuchty; Stephan Züchner
Journal:  Sci Rep       Date:  2019-02-08       Impact factor: 4.379

7.  A Complex Phenotype of a Patient with Spastic Paraplegia Type 4 Caused by a Novel Pathogenic Variant in the SPAST Gene.

Authors:  Yuichi Akaba; Ryo Takeguchi; Ryosuke Tanaka; Satoru Takahashi
Journal:  Case Rep Neurol       Date:  2021-12-07

8.  Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Authors:  Xiaoming Jia; Lohith Madireddy; Stacy Caillier; Adam Santaniello; Federica Esposito; Giancarlo Comi; Olaf Stuve; Yuan Zhou; Bruce Taylor; Trevor Kilpatrick; Filippo Martinelli-Boneschi; Bruce A C Cree; Jorge R Oksenberg; Stephen L Hauser; Sergio E Baranzini
Journal:  Ann Neurol       Date:  2018-07-03       Impact factor: 10.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.